Screener
Absci Corporation ABSI Business Segments — Other Noncash Income (Expense)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Absci Corporation in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The source filing: Absci Corporation’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:24 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001672688-26-000088
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Drug creation programs and platform (1) | $6,083 | $3,992 |
| External preclinical and clinical development (2) | 4,287 | 2,684 |
| Personnel (3) | 9,246 | 9,865 |
| Stock-based compensation | 4,380 | 4,943 |
| General & administrative | 4,334 | 4,338 |
| Depreciation and amortization | 2,728 | 3,072 |
| Other (gain)/loss, net (4) | 3 | 14 |
| Total operating expenses | $31,061 | $28,908 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Absci Corporation's business segments — other noncash income (expense)?
- Absci Corporation (ABSI) reported business segments — other noncash income (expense) of -$3K in Q1 2026.
- How has Absci Corporation's business segments — other noncash income (expense) changed year-over-year?
- Absci Corporation's business segments — other noncash income (expense) increased by 78.6% year-over-year, from -$14K to -$3K.
- What does business segments — other noncash income (expense) mean?
- Includes non-cash financial impacts such as adjustments to asset valuations, unrealized gains or losses, or other accounting entries that do not involve immediate cash flow. This metric is essential for reconciling the segment's GAAP results with its underlying cash-generating capability.
Ask your AI about Absci Corporation's business segments — other noncash income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude